National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Search
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Myelodysplastic/Myeloproliferative Diseases Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 02/22/2008



General Information About Myelodysplastic/Myeloproliferative Diseases






Chronic Myelomonocytic Leukemia






Juvenile Myelomonocytic Leukemia






Atypical Chronic Myelogenous Leukemia






Myelodysplastic/Myeloproliferative Disease, Unclassifiable







Stages of Myelodysplastic/Myeloproliferative Diseases






Treatment Option Overview






Treatment Options for Myelodysplastic/Myeloproliferative Diseases






Get More Information From NCI






Changes to This Summary (02/22/2008)






About PDQ



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

NIH Calendar of Events

Español
NCI Highlights
New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

President's Cancer Panel Annual Report: 2006-2007

Cancer Trends Progress Report: 2007 Update

Past Highlights
HPV Vaccines for Cervical Cancer
Stages of Myelodysplastic/Myeloproliferative Diseases

Staging is the process used to find out how far the cancer has spread. There is no standard staging system for myelodysplastic/myeloproliferative diseases. Treatment is based on the type of myelodysplastic/myeloproliferative disease the patient has. It is important to know the type in order to plan treatment.

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov